Gene therapy-based treatment such as optogenetics offers a potentially powerful way to bypass damaged photoreceptors in retinal degenerative diseases and use the remaining retinal cells for functionalization to achieve photosensitivity. However, current approaches of optogenetic treatment rely on opsins that require high intensity light for activation thus adding to the challenge for use as part of a wearable device. Here, we report AAV2 assisted delivery of highly photosensitive multi-characteristic opsin (MCO1) into ON-bipolar cells of mice with retinal degeneration to allow activation by ambient light. Rigorous characterization of delivery efficacy by different doses of AAV2 carrying MCO1 (vMCO1) into targeted cells showed durable expression over 6 months after delivery as measured by reporter expression. The enduring MCO1 expression was correlated with the significantly improved behavioral outcome, that was longitudinally measured by visual water-maze and optomotor assays. The pro/anti-inflammatory cytokine levels in plasma and vitreous humor of the vMCO1-injected group did not change significantly from baseline or control group. Furthermore, biodistribution studies at various time points after injection in animal groups injected with different doses of vMCO1 showed non-detectable vector copies in non-targeted tissues. Immunohistochemistry of vMCO1 transfected retinal tissues showed bipolar specific expression of MCO1 and the absence of immune/inflammatory response. Furthermore, ocular imaging using SD-OCT showed no change in the structural architecture of vMCO1-injected eyes. Induction of ambient light responsiveness to remaining healthy bipolar cells in subjects with retinal degeneration will allow the retinal circuitry to gain visual acuity without requiring an active stimulation device.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009;460:225–U87.
Schuchard RA, Naseer S, de Castro K. Characteristics of AMD patients with low vision receiving visual rehabilitation. J Rehabil Res Dev. 1999;36:294–302.
Yang ZL, Camp NJ, Sun H, Tong ZZ, Gibbs D, Cameron DJ, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science. 2006;314:992–3.
Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419–21.
Humayun M, Dorn J, da Cruz L. Interim results from the international trial of Second Sight’s visual prosthesis. Ophthalmology. 2012;119:779–88.
Pan ZH, Lu Q, Bi A, Dizhoor AM, Abrams GW. Optogenetic approaches to restoring vision. Annu Rev Vis Sci. 2015;1:185–210.
Sahel JA, Roska B. Gene therapy for blindness. Annu Rev Neurosci. 2013;36:467–88.
Zrenner E. Will retinal implants restore vision? Science. 2002;295:1022–5.
Humayun MS. Intraocular retinal prosthesis. Trans Am Ophthalmol Soc. 2001;99:271–300.
Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med. 2012;18:791–8.
Humayun MS, Weiland JD, Fujii GY, Greenberg R, Williamson R, Little J, et al. Visual perception in a blind subject with a chronic microelectronic retinal prosthesis. Vis Res. 2003;43:2573–81.
Margalit E, Maia M, Weiland JD, Greenberg RJ, Fujii GY, Torres G, et al. Retinal prosthesis for the blind. Surv Ophthalmol. 2002;47:335–56.
Zrenner E. Fighting blindness with microelectronics. Sci Transl Med. 2013;5:210ps16.
Hetling JR, Baig-Silva MS. Neural prostheses for vision: designing a functional interface with retinal neurons. Neurol Res. 2004;26:21–34.
Palanker D, Vankov A, Huie P, Baccus S. Design of a high-resolution optoelectronic retinal prosthesis. J Neural Eng. 2005;2:S105–20.
Horsager A, Greenwald SH, Weiland JD, Humayun MS, Greenberg RJ, McMahon MJ, et al. Predicting visual sensitivity in retinal prosthesis patients. Investig Ophthalmol Vis Sci. 2009;50:1483–91.
de Balthasar C, Patel S, Roy A, Freda R, Greenwald S, Horsager A, et al. Factors affecting perceptual thresholds in epiretinal prostheses. Investig Ophthalmol Vis Sci. 2008;49:2303–14.
Zrenner E, Bartz-Schmidt KU, Benav H, Besch D, Bruckmann A, Gabel VP, et al. Subretinal electronic chips allow blind patients to read letters and combine them to words. Proc Biol Sci. 2011;278:1489–97.
Chow AY, Pardue MT, Perlman JI, Ball SL, Chow VY, Hetling JR, et al. Subretinal implantation of semiconductor-based photodiodes: durability of novel implant designs. J Rehabil Res Dev. 2002;39:313–21.
Zrenner E. Will retinal implants restore vision? Science. 2002;295:1022–5.
Banghart M, Borges K, Isacoff E, Trauner D, Kramer RH. Light-activated ion channels for remote control of neuronal firing. Nat Neurosci. 2004;7:1381.
Caporale N, Kolstad KD, Lee T, Tochitsky I, Dalkara D, Trauner D, et al. LiGluR restores visual responses in rodent models of inherited blindness. Mol Ther. 2011;19:1212–9.
Polosukhina A, Litt J, Tochitsky I, Nemargut J, Sychev Y, De Kouchkovsky I, et al. Photochemical restoration of visual responses in blind mice. Neuron. 2012;75:271–82.
Wright W, Gajjeraman S, Batabyal S, Pradhan S, Bhattacharya S, Mahapatra V, et al. Restoring vision in mice with retinal degeneration using multicharacteristic opsin. Neurophotonics. 2017;4:041505.
Batabyal S, Cervenka G, Ha JH, Kim YT, Mohanty S. Broad-band activatable white-opsin. PLoS ONE. 2015;10:e0136958.
Tochitsky I, Kramer RH. Optopharmacological tools for restoring visual function in degenerative retinal diseases. Curr Opin Neurobiol. 2015;34:74–8.
Barrett JM, Berlinguer-Palmini R, Degenaar P. Optogenetic approaches to retinal prosthesis. Vis Neurosci. 2014;31:345–54.
Marc R, Pfeiffer R, Jones B. Retinal prosthetics, optogenetics, and chemical photoswitches. ACS Chem Neurosci. 2014;5:895–901.
Garg SJ, Federman J. Optogenetics, visual prosthesis and electrostimulation for retinal dystrophies. Curr Opin Ophthalmol. 2013;24:407–14.
Wu C, Ivanova E, Zhang Y, Pan ZH. rAAV-mediated subcellular targeting of optogenetic tools in retinal ganglion cells in vivo. PLoS ONE. 2013;8:e66332.
Goetz GA, Mandel Y, Manivanh R, Palanker DV, Cizmar T. Holographic display system for restoration of sight to the blind. J Neural Eng. 2013;10:056021.
Macé E, Caplette R, Marre O, Sengupta A, Chaffiol A, Barbe P, et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. Mol Ther. 2015;23:7–16.
Busskamp V, Duebel J, Balya D, Fradot M, Viney TJ, Siegert S, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science. 2010;329:413–7.
Schiller PH, Sandell JH, Maunsell JH. Functions of the ON and OFF channels of the visual system. Nature. 1986;322:824.
Hodges H. Maze procedures: the radial-arm and water maze compared. Brain Res Cogn Brain Res. 1996;3:167–81.
Prusky GT, Alam NM, Beekman S, Douglas RM. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Investig Ophthalmol Vis Sci. 2004;45:4611–6.
Douglas RM, Alam NM, Silver BD, McGill TJ, Tschetter WW, Prusky GT. Independent visual threshold measurements in the two eyes of freely moving rats and mice using a virtual-reality optokinetic system. Vis Neurosci. 2005;22:677–84.
Tomita H, Sugano E, Isago H, Hiroi T, Wang Z, Ohta E, et al. Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind rats. Exp Eye Res. 2010;90:429–36.
Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther. 2000;7:31–4.
Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346–58.
Doroudchi MM, Greenberg KP, Liu J, Silka KA, Boyden ES, Lockridge JA, et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther. 2011;19:1220–9.
Gaub BM, Berry MH, Visel M, Holt A, Isacoff EY, Flannery JG. Optogenetic retinal gene therapy with the light gated GPCR vertebrate rhodopsin. Retinal Gene Ther. 2018;1715:177–89.
Berry MH, Holt A, Salari A, Veit J, Visel M, Levitz J, et al. Restoration of high-sensitivity and adapting vision with a cone opsin. Nature Commun. 2019;10:1–12.
Mohanty S, Bhattacharya S, inventors; Nanoscope Technologies LLC, assignee. Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof. Australia patent 2017372351. 2017.
Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinform. 2012;13:134.
Brankatschk R, Bodenhausen N, Zeyer J, Burgmann H. Simple absolute quantification method correcting for quantitative PCR efficiency variations for microbial community samples. Appl Environ Microbiol. 2012;78:4481–9.
Liu Y, McDowell CM, Zhang Z, Tebow HE, Wordinger RJ, Clark AF. Monitoring retinal morphologic and functional changes in mice following optic nerve crush. Investig Ophthalmol Vis Sci. 2014;55:3766–74.
Kim BJ, Silverman SM, Liu Y, Wordinger RJ, Pang IH, Clark AF. In vitro and in vivo neuroprotective effects of cJun N-terminal kinase inhibitors on retinal ganglion cells. Mol Neurodegener. 2016;11:30.
Kim BJ, Sprehe N, Morganti A, Wordinger RJ, Clark AF. The effect of postmortem time on the RNA quality of human ocular tissues. Mol Vis. 2013;19:1290–5.
The authors would like to thank Dr. John Repass (ARQ Genetics) for QPCR analysis; Ashutosh Tripathy and Vasu Mahapatra for their help in experiments. The authors would also like to acknowledge proofread by Dr. Darryl Narcisse (Nanoscope) and support from the National Institute of Health (1R01EY025717-01A1, 1R43EY026483-01, 1R43EY025905-01, 1R01 EY028216-01A1, and 2R44EY025905-02A1).
Conflict of interest
SM and SBh have equity interest in Nanoscope Technologies, LLC, which is developing products in Biomedical diagnostics and therapeutic technologies.
All experimental procedures were conducted according to the Nanoscope Technologies’ Institutional Animal Care and Use Committee approved protocol and standard operating procedures (SOPs).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Batabyal, S., Gajjeraman, S., Pradhan, S. et al. Sensitization of ON-bipolar cells with ambient light activatable multi-characteristic opsin rescues vision in mice. Gene Ther (2020). https://doi.org/10.1038/s41434-020-00200-2